Literature DB >> 10639634

Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb.

.   

Abstract

Entities:  

Year:  1997        PMID： 10639634     DOI： 10.1023/a:1008880829137

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  6 in total

1.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1996-09-12       Impact factor: 91.245

Review 2.  Thrombin hypothesis of thrombus generation and vascular lesion formation.

Authors:  L A Harker; S R Hanson; M S Runge
Journal:  Am J Cardiol       Date:  1995-02-23       Impact factor: 2.778

3.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

Authors:  J I Weitz; M Hudoba; D Massel; J Maraganore; J Hirsh
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

4.  Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.

Authors:  L V Lee
Journal:  Am J Cardiol       Date:  1995-01-01       Impact factor: 2.778

5.  A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.

Authors:  C P Cannon; C H McCabe; T D Henry; M J Schweiger; R S Gibson; H S Mueller; R C Becker; N S Kleiman; J M Haugland; J L Anderson
Journal:  J Am Coll Cardiol       Date:  1994-04       Impact factor: 24.094

6.  Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.

Authors:  E M Antman
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.